Merck gets fast track designation from the USFDA for anticoagulant therapy

Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis

BMS–Pfizer expands Eliquis access through Cost Plus Drug setting $345 monthly price

The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform

Boston Scientific surges into 2026 with double-digit sales growth & record quarterly profit jump

Growth was broad-based across segments

Bayer flags major Phase III results for stroke prevention drug asundexian

The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy

First patient dosed in trial of novel drug targeting limb-threatening artery disease

The trial will enroll up to 42 patients in Finland across four cohorts

Bristol Myers Squibb, Johnson & Johnson halt major heart-drug trial after disappointing results

TAHO Pharma submits NDA to FDA for world’s first Apixaban oral dissolving film

Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes

Lupin receives FDA approval Rivaroxaban for oral suspension

The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India

Shilpa Medicare receives initial authorization for Rivaroxaban Orodispersible films from EMA

Akums demonstrates clinical versatility of Lacosamide in epilepsy care

Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.